Thyroid hormones for acute kidney injury

Area of Science:

• Nephrology
• Endocrinology
• Critical Care Medicine

Background:

• Acute kidney injury (AKI) is a common and serious condition in hospitalized patients with increasing incidence and poor outcomes.
• Existing treatments for AKI have shown limited improvement over the past four decades, necessitating exploration of novel therapeutic agents.
• Thyroid hormone therapy has shown potential in animal studies but lacks robust clinical evidence for AKI management.

Purpose of the Study:

• To systematically evaluate the benefits and harms of thyroid hormone therapy in adult patients hospitalized with acute kidney injury (AKI).

Main Methods:

• Searched major databases (Cochrane Renal Group, CENTRAL, MEDLINE, EMBASE) up to November 2012.
• Included randomized controlled trials (RCTs) and quasi-RCTs comparing thyroid hormone therapy with placebo or supportive treatments in adult AKI patients.
• Assessed study quality using Cochrane Collaboration's risk of bias tool; planned analysis of dichotomous (death, RRT) and continuous (hospital stay, AKI duration) outcomes.

Main Results:

• Two small studies (97 participants) met inclusion criteria, with significant differences in populations and interventions, precluding meta-analysis.
• One study indicated thyroid hormone therapy significantly increased all-cause mortality (RR 3.32) and prolonged AKI and renal replacement therapy (RRT) duration.
• No significant differences in RRT need were observed; data on ESKD progression and kidney function were inadequate. Both studies had suboptimal quality.

Conclusions:

• A lack of large, high-quality studies limits definitive conclusions on thyroid hormone therapy for established AKI.
• Current evidence suggests thyroid hormone therapy may be associated with adverse outcomes and should be avoided in patients with established AKI.
• The potential role of thyroid hormone therapy in AKI prevention warrants further investigation in future clinical studies.